-
Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Three New Drugs
•
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clinical trial approvals for three in-house developed drug candidates: HRS-1780, HRS-1358, and SHR-7367. These approvals mark significant milestones in the company’s pipeline development, positioning Hengrui to advance innovative treatments for chronic kidney disease and advanced malignant tumors. HRS-1780 ProfileHRS-1780 is an…
-
Rainsure Scientific Secures Series C1 Funding for Digital PCR Development
•
Rainsure Scientific, a Suzhou-based developer of digital PCR instruments and RUO detection kits, has reportedly raised “tens of millions” of renminbi in a Series C1 financing round led by Qiaodao Investment Fund. The proceeds will be used to further develop and commercialize the company’s innovative molecular diagnostics products. Company ProfileFounded…
-
CSPC Pharma’s rhTNK-tPA Accepted for Review by NMPA for Stroke Indication
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that a supplementary market filing for its recombinant human TNK tissue-type plasminogen activator for injection (rhTNK-tPA) has been accepted for review by the National Medical Products Administration (NMPA). The new indication filing is for the drug’s use as a thrombolytic therapy…
-
Asia Pacific Medical Group Secures Series A Funding for Hospital Expansion
•
Private healthcare group Asia Pacific Medical Group (APMG) has raised “hundreds of millions” of renminbi in a Series A financing round. The round was led by IDG Capital and the People’s Insurance Company of China (PICC), with participation from GL Capital. The proceeds will be used for the late phase…
-
Haisco’s HSK31858 Gains Ethical Approval for Phase II Study in NCFBE
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its drug candidate HSK31858 obtained ethical approval at the First Affiliated Hospital of Guangzhou Medical University. The in-house developed Category 1 drug will be assessed for its efficacy and safety in a multi-center, randomized, double-blind, placebo-controlled Phase II study…
-
CANbridge’s CAN106 Receives Orphan Drug Designation for Myasthenia Gravis
•
China-based rare disease firm CANbridge Pharmaceuticals Inc. (HKG: 1228) has announced receiving Orphan Drug Designation (ODD) status for its pipeline drug candidate CAN106, a long-acting monoclonal antibody (mAb) targeting C5 of the complement system, for use in myasthenia gravis (MG). Myasthenia gravis is a rare and chronic autoimmune disease caused…
-
HitGen Partners with Guangzhou AIChemEco for Automated Synthesis Technology
•
China-based HitGen Inc. (SHA: 688222) has announced a partnership with compatriot firm Guangzhou AIChemEco. The collaboration aims to advance the development and application of automated high-throughput synthesis technology, project undertaking and delivery, and the design and construction of a new compound library. Financial details of the partnership were not disclosed.…
-
Harbour BioMed Establishes Nona Biosciences for Next-Generation Antibody Development
•
Harbour BioMed (HKG: 2142), a biotech company with operations in the Netherlands, the United States, and China, has announced the establishment of a new wholly-owned subsidiary, Nona Biosciences. The new unit will provide R&D solutions to clients for next-generation antibodies and other biotherapeutic development, covering the entire spectrum from discovery…
-
Novartis Considers Sale of Non-Core Units to Fund Innovation
•
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly considering the sale of certain ‘non-core’ business units, according to unnamed insider sources cited by Bloomberg. The move aims to raise funds to support further innovation in core areas. The company is said to be evaluating its options for its respiratory…
-
Sequanta Technologies Partners with Illumina to Introduce NovaSeq X Series
•
Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, has entered into a cooperation intention agreement with Illumina (NASDAQ: ILMN) at the 5th China International Import Expo (CIIE). The deal will lead to the introduction of Illumina’s latest NovaSeq X high throughput sequencer series products. Financial details…
-
Ascletis Pharma’s PD-L1 Inhibitor ASC61 Gains NMPA IND Approval
•
China-based Ascletis Pharma Inc. (HKG: 1672) has announced the approval of the Investigational New Drug (IND) application by China National Medical Products Administration (NMPA) for its in-house developed oral programmed-death ligand 1 (PD-L1) small molecule inhibitor ASC61. This approval will accelerate the global development of the drug, which is currently…
-
MicroTech Medical Plans IPO on Shanghai’s STAR Market
•
China-based diabetes specialist MicroTech Medical (Hangzhou) Co., Ltd (HKG: 2235) has announced plans to conduct an initial public offering (IPO) of 93.46 million shares on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The listing price remains unknown at this stage. Company ProfileFounded in 2011, MicroTech Medical specializes in diabetes…
-
Gracell’s FasTCAR Platform Wins Fierce Life Sciences Innovation Award
•
China-based Gracell Biotechnologies Inc’s (Nasdaq.GRCL) FasTCAR technology platform has been named the winner of this year’s Fierce Life Sciences Innovation Award. The announcement was made by Gracell CEO William Wei Cao during the firm’s Q3 earnings conference call. The FasTCAR platform enables the “next-day manufacture” of autologous chimeric antigen receptor…
-
Walvax Biotechnology Expands Manufacturing Partnership with Etana for PCV and HPV Vaccines
•
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has entered into another manufacturing cooperation agreement with Indonesia-based PT Etana Biotechnologies (Etana) for PCV and HPV vaccines. This builds on an earlier agreement for Etana to provide local manufacturing of Walvax Bio’s COVID-19 mRNA vaccine in Indonesia. Financial details of the partnership…
-
Simcere Pharmaceuticals Licenses Idorsia’s Insomnia Therapy Daridorexant for Greater China
•
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the establishment of a licensing agreement with Swiss firm Idorsia Ltd, securing exclusive development and commercialization rights to Idorsia’s insomnia therapy daridorexant in Greater China, including mainland China, Hong Kong, and Macau. The agreement also includes clinical research and development (R&D) activities.…
-
Sirnaomics Announces Key Executive Promotions Effective November 15
•
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced key changes to its C-suite, effective as of November 15, 2022. These leadership moves reflect the company’s strategic focus on growth and operational excellence. CFO PromotionYe Yongji, former China Chief Financial Officer (CFO), has been promoted to group CFO, vice-president…
-
Hengrui Pharmceuticals’ SHR0302 Achieves Positive Results in Phase III Atopic Dermatitis Study
•
China-based Jiangsu Hengrui Pharmceuticals (SHA: 600276) has announced positive results from the randomized, double-blind, placebo-controlled, multi-center RSJ10333 (QUARTZ3) Phase III study for SHR0302 in atopic dermatitis. The study, conducted by Hengrui’s subsidiary Reistone Biopharma Co., Ltd, has reached the pre-set primary efficacy endpoint. Study DetailsThe RSJ10333 study was designed to…
-
Kanghong Pharma Gains NMPA Approval for Innovative Eye Injection KH631
•
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving clinical trial approvals from the National Medical Products Administration (NMPA) for its Category 1 innovative eye injection KH631 and a generic version of Acadia Pharmaceuticals Inc’s pimavanserin. The approvals are for the treatment of neovascular (wet) age-related macular…
-
Antengene’s ATG-008 Shows Promising Results in Cervical Cancer and Hepatocellular Carcinoma Studies
•
Shanghai-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced positive preliminary results from the TORCH-2 study (NCT04337463) for its mTORC1/2 inhibitor ATG-008 (onatasertib) in combination with the programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) for recurrent/metastatic cervical cancer. The company also released data from the TORCH study for ATG-008 monotherapy in…
-
CStone Pharmaceuticals Launches AML Public Welfare Project with China Social Welfare Foundation
•
The acute myeloid leukemia (AML) public welfare project, initiated by the China Social Welfare Foundation (CSWF) and sponsored by CStone Pharmaceuticals (HKG: 2616), has officially been launched. This initiative aims to raise awareness and support for AML, a disease that disproportionately affects the elderly and progresses rapidly. AML ContextAcute myeloid…
